IncyteMEX:INCY 84 Days Payable is 191.34 as of Mar. 2026, which is 39% below its 10-year median of 313.44. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,470.96 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Incyte ranks better than 62.07% on this metric.
Incyte's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN3,951 Mil. Incyte's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN1,884 Mil.
Hence, Incyte's Days Payable for the
three
months ended in Mar. 2026 was 191.34.
The historical rank and industry rank for Incyte's Days Payable or its related term are showing as below:
MEX:INCY'
s Days Payable Range Over the Past 10 Years
Min: 179.56 Med: 313.44 Max: 396.44
Current: 189.49
During the past 13 years, Incyte's highest Days Payable was 396.44. The lowest was 179.56. And the median was 313.44.
MEX:INCY's Days Payable is ranked better than 62.07% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs MEX:INCY: 189.49
Incyte's Days Payable
declined
from Mar. 2025 (247.35) to Mar. 2026 (191.34).
It may suggest that Incyteaccelerated paying its suppliers.
Incyte Days Payable Related Terms
Incyte Days Payable Historical Data
* Premium members only.
The historical data trend for Incyte's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: Days Payable Comparison
For the Biotechnology subindustry, Incyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's Days Payable distribution charts can be found below:
* The bar in red indicates where Incyte's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Incyte's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a Days Payable of 191.34 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Incyte and its competitors. This is 39% below median its historical median of 313.44. Over the past decade, Incyte's Days Payable has ranged from 179.56 to 396.44. According to the industry distribution chart, Incyte ranks #267 out of 704 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Incyte's Days Payable too high?
Incyte's current Days Payable of 191.34 is 39% below median its 10-year median of 313.44. Over the past 10 years, this metric has ranged from a low of 179.56 to a high of 396.44. The Biotechnology industry median Days Payable is 113.56. Incyte's value of 191.34 is 68.5% above this industry median. Based on the distribution chart, Incyte ranks #267 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Days Payable compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #267 out of 704 companies for Days Payable. This puts Incyte in the upper half of its industry. The industry median Days Payable is 113.56. Incyte's value of 191.34 is 68.5% above this benchmark. Historically, Incyte's own Days Payable has ranged from 179.56 to 396.44 over the past decade. While the company's 10-year median is 313.44 vs. the industry median of 113.56, Incyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current Days Payable of 191.34 is 68.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Incyte and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Days Payable is 191.34, which is 39% below median its own 10-year median of 313.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,470.96, compared to a current price of MXN1,676.03 — trading 13.9% above its estimated fair value. The current Days Payable is 191.34, which is 39% below median its 10-year median of 313.44 and 68.5% above the Biotechnology industry median of 113.56. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Days Payable is 191.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN1,676.03 is trading 13.9% above its estimated GF Value™ of MXN1,470.96.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
Days Payable: 191.34 (39% below median its 10-year median of 313.44)
GF Value™: MXN1,470.96 vs. price of MXN1,676.03 (13.9% above fair value)
Industry Position: 68.5% above the Biotechnology median (#267 of 704)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
